reports
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Guy Sips
Agfa Final resolution of price adjustment related to sale of Offset to...
In a press release -in which adherence to legal exactitude substantially compromised the clarity of the communication- Agfa announced the final resolution of the purchase price adjustment related to the 2022 sale of its Offset Solutions division to Aurelius. After contacting Agfa's management, it became clear that -following the independent expert's ruling- Agfa should receive €19.9m in cash within 15 business days, bringing the miss in total cash receipts from the original receivable of € 31...
Agfa receives final expert ruling on receivable related to sale of Off...
Agfa receives final expert ruling on receivable related to sale of Offset Solutions division to Aurelius January 16, 2026 – 6.30 PM CET Regulated information Agfa receives final expert ruling on receivable related to sale of Offset Solutions division to Aurelius Mortsel, Belgium – January 16, 2026 – 6.30 p.m. CET Agfa has received the final report of the independent expert regarding the outstanding receivable under the share purchase agreement that was signed with Aurelius Group for the sale of Agfa’s Offset Solutions division. In August 2022, Ag...
Agfa ontvangt eindrapport van expert over vordering in verband met ver...
Agfa ontvangt eindrapport van expert over vordering in verband met verkoop van de Offset Solutions-divisie aan Aurelius 16 januari 2026 – 18u30 CET Gereglementeerde informatie Agfa ontvangt eindrapport van expert over vordering in verband met verkoop van de Offset Solutions-divisie aan Aurelius Mortsel, België – 16 januari 2026 – 18u30 CET Agfa heeft het eindrapport ontvangen van de onafhankelijke expert met betrekking tot de uitstaande vordering in het kader van de aandelenkoopovereenkomst die werd gesloten met Aurelius Group voor de verkoop van Agfa's Offset Solutions-divisie. In au...
Agfa announces additional measures to adjust the cost base of its trad...
Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn tra...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
- Guy Sips
Agfa “Shrinking Business” & “Not-So-Growth Engines”
After three quarters, Agfa's 9M25 “Mature Business” (Radiology and Film DPC) sales dropped -6.4% y/y, driven by the accelerating medical film decline. While its “Growth Engines” (HealthCare IT, Digital Printing Solutions, Green Hydrogen Solutions) are intended to offset this, they also fell -0.9% y/y in the first nine months. We remain cautious (Hold; €1.0 Target Price) until strategic measures deliver and growth engines regain momentum.
- Guy Sips
Agfa Decline in medical film was even stronger than expected
Agfa's 3Q25 continued decline in medical film was even stronger than expected (€ 257m 3Q25 sales vs € 275m KBCS & CSS). Although the growth in cloud/SaaS in HealthCare IT all the divisions were below our and CSS forecasts as well on top-line as on REBIT-margins. The increase in Digital Printing & Chemicals was not sufficiently offsetting the impact from the decline in medical film and from cloud transition in HealthCare IT. Despite good cost control, REBIT decreased to -4m, mainly due to the d...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, ...
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Regulated information November 13, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Group performance: Top line decrease of 7.1% (-4.7% currency comparable): increase in Digital Printing & Chemicals not sufficiently offsetting impact from decline in medical...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende ach...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Gereglementeerde informatie 13 november 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Groepsprestatie: Omzetdaling van 7,1% (-4.7% zonder wisselkoerseffecten): stijging ...
- Guy Sips
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
Crescent NV: 2 directors
Two Directors at Crescent NV bought/sold 95,490,000 shares at between 0.007EUR and 0.007EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.